Genenta Shares Slide on $15M Fundraising Announcement

Genenta Science ($GNTA) shares tumbled 27% after the company said it entered into a $15 million securities purchase agreement with institutional investors to strengthen its balance sheet and support operations.

Under the agreement, Genenta will issue 4.29 million American Depositary Shares (ADSs) at $3.50 per share, with no warrants attached — a pricing structure aimed at simplifying the capital raise.

Use of Proceeds and Financial Outlook

The company said the net proceeds will be used for:

Working capital
General corporate purposes
Ongoing clinical and operational initiatives

The financing is expected to close on or around October 28, 2025, subject to customary closing conditions.

Market Reaction

Investors reacted negatively to the equity dilution, sending Genenta shares down 27% in Friday trading. Despite the sharp decline, the raise extends the company’s operational runway, offering flexibility to advance its gene-therapy pipeline.

Background

Genenta focuses on developing hematopoietic stem cell gene therapies for solid and hematologic cancers. The company continues to progress its Temferon platform, which uses genetically modified cells to deliver therapeutic payloads directly to the tumor microenvironment.